WO2002018350A1 - Inhibiteur grk - Google Patents

Inhibiteur grk Download PDF

Info

Publication number
WO2002018350A1
WO2002018350A1 PCT/JP2001/007397 JP0107397W WO0218350A1 WO 2002018350 A1 WO2002018350 A1 WO 2002018350A1 JP 0107397 W JP0107397 W JP 0107397W WO 0218350 A1 WO0218350 A1 WO 0218350A1
Authority
WO
WIPO (PCT)
Prior art keywords
ring
grk inhibitor
represents optionally
grk
inhibitor
Prior art date
Application number
PCT/JP2001/007397
Other languages
English (en)
Japanese (ja)
Inventor
Shoji Fukumoto
Toshifumi Watanabe
Shota Ikeda
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to AU2001282520A priority Critical patent/AU2001282520A1/en
Publication of WO2002018350A1 publication Critical patent/WO2002018350A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouvel inhibiteur GRK qui contient un composé représenté par la formule (I), un sel du composé, ou un promédicament renfermant l'un des deux, formule dans laquelle le noyau A représente un hétérocycle éventuellement substitué contenant de l'azote, R1 et R2 représentent amino, et X représente un espaceur comprenant une partie linéaire constituée d'un à quatre atomes, à condition que R1 puisse être lié à R2 et/ou à X pour former un noyau. L'inhibiteur est utile dans la prévention ou le traitement des défaillances cardiaques, etc.
PCT/JP2001/007397 2000-08-29 2001-08-29 Inhibiteur grk WO2002018350A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001282520A AU2001282520A1 (en) 2000-08-29 2001-08-29 Grk inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000264499 2000-08-29
JP2000-264499 2000-08-29

Publications (1)

Publication Number Publication Date
WO2002018350A1 true WO2002018350A1 (fr) 2002-03-07

Family

ID=18751904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/007397 WO2002018350A1 (fr) 2000-08-29 2001-08-29 Inhibiteur grk

Country Status (2)

Country Link
AU (1) AU2001282520A1 (fr)
WO (1) WO2002018350A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037271A2 (fr) * 2003-10-17 2005-04-28 Tanabe Seiyaku Co., Ltd. Agent d'ouverture de canaux k actives par le calcium a conductance elevee
WO2008001883A1 (fr) 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. DÉRIVÉ D'ACIDE α-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
US7482350B2 (en) 2004-05-08 2009-01-27 Neurogen Corporation 4,5-disubstituted-2-aryl pyrimidines
US8748442B2 (en) 2010-06-30 2014-06-10 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63126868A (ja) * 1986-10-18 1988-05-30 ザ　ウエルカム　フアウンデーシヨン　リミテツド 化合物またはその塩、これらを含む医薬製剤、動物の腫瘍増殖の治療または予防方法、該化合物の製造方法、および新規な化学中間体
JPH029869A (ja) * 1988-04-15 1990-01-12 Wellcome Found Ltd:The 新規化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63126868A (ja) * 1986-10-18 1988-05-30 ザ　ウエルカム　フアウンデーシヨン　リミテツド 化合物またはその塩、これらを含む医薬製剤、動物の腫瘍増殖の治療または予防方法、該化合物の製造方法、および新規な化学中間体
JPH029869A (ja) * 1988-04-15 1990-01-12 Wellcome Found Ltd:The 新規化合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIGHAM E.C.: "Multisubstrate analog inhibitors of glycinamide ribonucleotide transformylase based on 5-deazaacyclotetrahydrofolate (5-DACTHF)", HETEROCYCLES, vol. 35, no. 2, 1993, pages 1289 - 1307, XP002947298 *
BIGHAM E.C.: "Synthesis and biological activity of open-chain analogs of 5,6,7,8-tetrahydrofolic acid-potential antitumor agents", J. MED. CHEM., vol. 35, no. 8, 1992, pages 1399 - 1410, XP002947295 *
BOGER D.L.: "Multisubstrate analog based on 5,8,10-trideazafolate", BIOORG. MED. CHEM., vol. 5, no. 9, 1997, pages 1853 - 1857, XP002947299 *
HASBI A.: "Desesitization of the .delta.-opioid receptor correlates with its phosphorylation in SK-N-BE cells: Involvement of a G protein-coupled receptor kinase", J. NEUROCHEM., vol. 70, no. 5, 1998, pages 2129 - 2138, XP002947293 *
JANSEN M.: "Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression", BIOCHEM. PHARMACOL., vol. 47, no. 6, 1994, pages 1067 - 1078, XP002947294 *
KELLY J.L.: "Synthesis and biological activity of an acyclic analog of 5,6,7,8-tetrahydrofolic acid, N-(4-((3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl)amino)benzoyl)-L-glutamic acid", J. MED. CHEM., vol. 33, no. 2, 1990, pages 561 - 567, XP002947296 *
KLEIN C.: "Towards structure-based drug design: crystal structure of a multisubstrate adduct complex of glycinamide ribonucleotide transformylase at 1.96 .ANG.resolution", J. MOL. BIOL., vol. 249, no. 1, 1995, pages 153 - 175, XP002947300 *
STYLES V.L.: "Synthesis of the pentaglutymyl derivative of N-(4-(N-(3-(2,4-diamino-1,6-dihydro-6-oxo-5-pyrimidinyl)propyl)amino)benzoyl)-L-glutamic acid (5-DACTHF). An acyclic analog of tetrahydrofolic acid", J. HETEROCYCL. CHEM., vol. 27, no. 6, 1990, pages 1809 - 1813, XP002947297 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037271A2 (fr) * 2003-10-17 2005-04-28 Tanabe Seiyaku Co., Ltd. Agent d'ouverture de canaux k actives par le calcium a conductance elevee
WO2005037271A3 (fr) * 2003-10-17 2005-09-01 Tanabe Seiyaku Co Agent d'ouverture de canaux k actives par le calcium a conductance elevee
US7482350B2 (en) 2004-05-08 2009-01-27 Neurogen Corporation 4,5-disubstituted-2-aryl pyrimidines
US8129395B2 (en) 2004-05-08 2012-03-06 Novartis International Pharmaceutical Ltd. 4,5-disubstituted-2-aryl pyrimidines
WO2008001883A1 (fr) 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. DÉRIVÉ D'ACIDE α-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
US8748442B2 (en) 2010-06-30 2014-06-10 Ironwood Pharmaceuticals, Inc. sGC stimulators
US10189809B2 (en) 2010-06-30 2019-01-29 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators

Also Published As

Publication number Publication date
AU2001282520A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
DK0574545T3 (da) Phenylamidinderivater som blodpladeaggregationsinhibitorer
WO2002062792A1 (fr) Inhibiteur de jnk
WO2001017972A3 (fr) Nouveaux herbicides
WO2001070671A3 (fr) Anthranilamides insecticides
EP1471065A4 (fr) Nouveau compose 1,2,4-triazole
WO2001019828A3 (fr) Inhibiteurs de kinase utilises comme agents therapeutiques
EP1182195A4 (fr) Composes cycliques et leurs utilisations
ATE273305T1 (de) Thrombin-inhibitoren
MXPA04002647A (es) Antranilamidas artropodicidas.
EP1568699A4 (fr) Compose 1,3-dihydro-imidazole a cycle fusionne
WO1998005652A3 (fr) Amides cycliques arthropodicides et fongicides
EP1634874A4 (fr) Derive d'imidazolidine
WO2001072263A3 (fr) Utilisation d'ectoine ou de derives d'ectoine pour proteger la proteine du stress de la peau
WO2003049690A3 (fr) Inhibiteurs de l'integrase du vih
ID24846A (id) Turunan-turunan bifenilamidina
FI923033A (fi) N-fenyltioureaderivat och farmaceutisk anvaendning
WO2002018350A1 (fr) Inhibiteur grk
WO2004111008A3 (fr) Utilisation d'un compose de formule i pour la preparation d'une composition pharmaceutique
WO2003035650A1 (fr) Inhibiteur d'entree
EP1803719A4 (fr) Derive de 1h-triazole 1,5-diheterocyclique
MY129094A (en) Condensed polycyclic compounds
EP1362850A4 (fr) Compose d'oximether et bactericides agricole et horticoles
WO2004099130A3 (fr) Inhibiteur de cox
DK1340756T3 (da) Hidtil ukendte beta-lactamforbindelser og fremgangsmåde til fremstilling deraf
WO2001072287A3 (fr) Utilisation d'ectoine ou derives d'ectoine pour assurer la prophylaxie et/ou le traitement de l'immunodepression induite par u.v.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP